Laboratorios Farmaceuticos Rovi's revenue per share for the
three
months ended in Mar. 2026 was $3.45.
Laboratorios Farmaceuticos Rovi's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was $16.88.
Warning Sign:
Laboratorios Farmaceuticos Rovi SA revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Laboratorios Farmaceuticos Rovi was -26.10% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -1.70% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 12.10% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 14.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Revenue per Share or its related term are showing as below:
LABFF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.7 Med: 10.7 Max: 30.3
Current: -1.7
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest 3-Year average Revenue Per Share Growth Rate was 30.30% per year. The lowest was -1.70% per year. And the median was 10.70% per year.
LABFF's 3-Year Revenue Growth Rate is ranked worse than 65.56% of 900
companies
in the Drug Manufacturers industry
Industry Median: 3.8
vs LABFF: -1.70
Laboratorios Farmaceuticos Rovi (OTCPK:LABFF) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Laboratorios Farmaceuticos Rovi Revenue per Share Related Terms
Laboratorios Farmaceuticos Rovi Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi Revenue per Share Chart
LABFF vs ZTS, UTHR, VTRS: Revenue per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's PS Ratio distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's PS Ratio falls into.
Laboratorios Farmaceuticos Rovi Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.88
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (LABFF) has a Revenue per Share of $16.88 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #590 out of 900 companies in the Drug Manufacturers industry, placing it in the top 65.6%.
Is Laboratorios Farmaceuticos Rovi's Revenue per Share too high?
Laboratorios Farmaceuticos Rovi's current Revenue per Share is $16.88. The Drug Manufacturers industry median Revenue per Share is 3.80. Laboratorios Farmaceuticos Rovi's value of $16.88 is 344.2% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #590 out of 900 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Revenue per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #590 out of 900 companies for Revenue per Share. This places Laboratorios Farmaceuticos Rovi in the lower half of its industry. The industry median Revenue per Share is 3.80. Laboratorios Farmaceuticos Rovi's value of $16.88 is 344.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Drug Manufacturers company?
The median Revenue per Share among Drug Manufacturers companies is 3.80, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Revenue per Share of $16.88 is 344.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Revenue per Share is 3.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Revenue per Share is $16.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Revenue per Share of $16.88. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current Revenue per Share is $16.88 and 344.2% above the Drug Manufacturers industry median of 3.80. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Revenue per Share is $16.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.
Key valuation signals for LABFF:
Revenue per Share: $16.88
GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
Industry Position: 344.2% above the Drug Manufacturers median (#590 of 900)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for LABFF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
